 I. To define the maximum tolerated dose MTD of OSI-774 erlotinib; Tarceva in combination with CCI-779 temsirolimus in patients with recurrent malignant glioma who are not taking enzyme-inducing anti-epileptic drugs EIAEDs. Phase I II. To characterize the safety profile of OSI-774 erlotinib and CCI-779 temsirolimus. Phase I III. To characterize the pharmacokinetics of OSI-774 erlotinib and CCI-779 temsirolimus. Phase I IV. To determine the efficacy of OSI-774 erlotinib and CCI-779 temsirolimus in patients with recurrent malignant glioma as measured by 6-month progression-free survival. Phase II 